
2026Q3 Medpace Holdings, Inc. (MEDP)
Medpace Holdings, Inc. operates within the global clinical Contract Research Organization (CRO) industry, providing scientifically driven, outsourced clinical development services to biotechnology, pharmaceutical, and medical device companies1. The CRO sector is a critical pillar of the global life sciences ecosystem, enabling biopharmaceutical sponsors to navigate complex multi-phase clinical trials (Phases I through IV) and stringent global regulatory approval frameworks overseen by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and international equivalents1 According to industry benchmarks disclosed in peer regulatory filings (such as IQVIA Holdings Inc.'s Form 10-K for the year ended December 31, 2025), global biopharmaceutical spending on research and development (R&D) totaled approximately $199.0 billion in 202513. Excluding preclinical discovery, the addressable clinical development spending market reached approximately $159.0 billion in 2025, up markedly from $99.0 billion in 202313. Of this $159.0 billion clinical development market, outsourced CRO penetration approaches 47%, representing a direct outsourced clinical CRO Total Addressable Market (TAM) of approximately $75.0 billion in 2025, compared to $50.0 billion in 202313. Furthermore, global pharmaceutical revenues reached $1.94 trillion in 2025, with emerging markets projected to expand at a 5% to 8% compound annual growth rate (CAGR) through 2030, driving sustained downstream demand for global multi-site clinical trial execution Within this $75.0 billion outsourced clinical TAM, the industry bifurcates into two distinct operational models1. The first is the Functional Service Provider (FSP) and large-cap hybrid model, which is utilized predominantly by top-20 global pharmaceutical companies that maintain internal clinical management infrastructure and outsource discrete functional tasks, such as clinical monitoring or biostatistics, to mega-CROs like IQVIA, ICON plc, PPD (Thermo Fisher Scientific), and Fortrea Holdings11. The second is the full-service outsourced clinical model, utilized primarily by small- and mid-sized biotechnology companies (firms with less than $250 million in annual revenue or emerging pre-commercial pipelines) that lack internal clinical trial execution teams and require an end-to-end partner to design, manage, and execute the entire clinical trial lifecycle
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
